Currently, there are 49.49M common shares owned by the public and among those 38.49M shares have been available to trade.
The company’s stock has a 5-day price change of 31.99% and 33.04% over the past three months. KALV shares are trading 30.84% year to date (YTD), with the 12-month market performance up to 77.80% higher. It has a 12-month low price of $7.30 and touched a high of $15.50 over the same period. KALV has an average intraday trading volume of 752.21K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.32%, 20.49%, and 37.59% respectively.
Institutional ownership of KalVista Pharmaceuticals Inc (NASDAQ: KALV) shares accounts for 88.43% of the company’s 49.49M shares outstanding.
It has a market capitalization of $748.71M and a beta (3y monthly) value of 0.03. The earnings-per-share (ttm) stands at -$3.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.17% over the week and 7.31% over the month.
Analysts forecast that KalVista Pharmaceuticals Inc (KALV) will achieve an EPS of -0.83 for the current quarter, -0.92 for the next quarter and -2.98 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.95 while analysts give the company a high EPS estimate of -0.95. Comparatively, EPS for the current quarter was -1.07 a year ago. Earnings per share for the fiscal year are expected to decrease by -2.83%, and 13.46% over the next financial year. EPS should grow at an annualized rate of 24.62% over the next five years, compared to -20.06% over the past 5-year period.
Looking at the support for the KALV, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on January 31, 2025, with the firm’s price target at $19. TD Cowen coverage for the KalVista Pharmaceuticals Inc (KALV) stock in a research note released on January 07, 2025 offered a Buy rating with a price target of $30. BofA Securities was of a view on December 18, 2024 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on June 15, 2020, issuing a price target of $30. SVB Leerink on their part issued Outperform rating on July 29, 2019.
